Quick Summary:
Navigating the global Monoclonal Antibodies business landscape has never been as crucial or complex. Technology advances, a post-pandemic resurgence, and evolving consumer needs are shifting the ground under this burgeoning industry projected to reach a value of US$266.8 Billion by 2030. Our comprehensive market research report is a cardinal resource that offers an inside look at this dynamic world, aiding business executives in making informed decisions without being taken by surprise.
From obtaining a profound understanding of the economic implications behind the US and China's robust market growth to assessing the competitive plans of industry powerhouses such as Abbott Diagnostics and AstraZeneca, our report provides pivotal insights that shape strategic decisions. Seize the opportunity to be at the forefront of your industry with our report, which boasts special features like online interactive peer-to-peer bespoke updates and complimentary reports for one year. Navigate the future effectively by equipping yourself with valuable data, analyses, and expert insights.
Global Monoclonal Antibodies Market to Reach $266.8 Billion by 2030
The global market for Monoclonal Antibodies estimated at US$156.5 Billion in the year 2022, is projected to reach a revised size of US$266.8 Billion by 2030, growing at a CAGR of 6.9% over the analysis period 2022-2030. Human, one of the segments analyzed in the report, is projected to record a 8.3% CAGR and reach US$105.2 Billion by the end of the analysis period. Taking into account the ongoing post pandemic recovery, growth in the Humanized segment is readjusted to a revised 7.1% CAGR for the next 8-year period.
The U.S. Market is Estimated at $42.6 Billion, While China is Forecast to Grow at 11.4% CAGR
The Monoclonal Antibodies market in the U.S. is estimated at US$42.6 Billion in the year 2022. China, the world's second largest economy, is forecast to reach a projected market size of US$62.1 Billion by the year 2030 trailing a CAGR of 11.4% over the analysis period 2022 to 2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 2.7% and 7.3% respectively over the 2022-2030 period. Within Europe, Germany is forecast to grow at approximately 4.1% CAGR. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$36.8 Billion by the year 2030.Select Competitors (Total 123 Featured) -
- Abbott Diagnostics, Inc. - Core Laboratory
- AbbVie, Inc.
- Amgen, Inc.
- AstraZeneca PLC
- Bristol-Myers Squibb Company
- Eli Lilly and Company
- F. Hoffmann-La Roche AG
- Johnson & Johnson
- Merck & Co., Inc.
- Novartis International AG
What's New?
- Special coverage on Russia-Ukraine war; global inflation; easing of zero-Covid policy in China and its `bumpy` reopening; supply chain disruptions, global trade tensions; and risk of recession.
- Global competitiveness and key competitor percentage market shares
- Market presence across multiple geographies - Strong/Active/Niche/Trivial
- Online interactive peer-to-peer collaborative bespoke updates
- Access to digital archives and Research Platform
- Complimentary updates for one year
What is the estimated value of the Global Market for Monoclonal Antibodies?
What is the growth rate of the Global Market for Monoclonal Antibodies?
What is the forecasted size of the Global Market for Monoclonal Antibodies?
Who are the key companies in the Global Market for Monoclonal Antibodies?
| Report Attribute | Details |
|---|---|
| No. of Pages | 213 |
| Published | September 2023 |
| Forecast Period | 2022 - 2030 |
| Estimated Market Value ( USD | $ 156.5 Billion |
| Forecasted Market Value ( USD | $ 266.8 Billion |
| Compound Annual Growth Rate | 6.9% |
| Regions Covered | Global |
Table of Contents
Companies Mentioned
A selection of companies mentioned in this report includes:
- Abbott Diagnostics, Inc. - Core Laboratory
- AbbVie, Inc.
- Amgen, Inc.
- AstraZeneca PLC
- Bristol-Myers Squibb Company
- Eli Lilly and Company
- F. Hoffmann-La Roche AG
- Johnson & Johnson
- Merck & Co., Inc.
- Novartis International AG
